阿托伐他汀对脑血栓患者血管细胞黏附分子-1表达的影响

目的观察阿托伐他汀对脑血栓患者细胞黏附分子-1表达的影响。方法随机选择66例脑血栓患者,36例在常规治疗基础上加服阿托伐他汀20mg治疗为阿托伐他汀组,30例常规治疗者作为常规治疗组,同时选用健康人群20名为对照组。研究组分别在发病(发病7天内)、3个月后、12个月后监测血脂及血管细胞黏附分子-1等指标的变化情况。结果①脑血栓患者在发病7天内血管黏附分子-1的表达水平较对照组升高,且差异有显著性(P<0.05)。②阿托伐他汀组在3个月及1年后血总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)较入院时明显降低,治疗前后结果比较差异有显著性(P<0.01)。③阿托伐他汀组与常规治疗组在治疗后3个月比较血管细胞黏附分子-1的表达明显下调,且差异有显著性。④阿托伐他汀组与常规治疗组在治疗后12个月比较血管细胞黏附分子-1的表达有差异,但无显著性差异(P>0.05)。结论①脑血栓患者急性期血管细胞黏附分子-1的表达明显上调;②阿托伐他汀具有明显的降血脂作用,并且在急性期具有降低血管细胞黏附分子-1的作用。

Effect of atorvastatin on sVCAM-1 in cerebral thrombosis

Objective To observe the effect of atorvastatin on sVCAM-1 in patients with cerebral thrombosis. Methods 66 patients with acute cerebral thrombosis were divided into two groups randomly. 36 cases were given atorvastatin 20 mg every day and basic treatment as atorvastatin group , the other 30 cases were only given basic treatment as basic treatment group, 20 healthy age matched individuals as control group. We examined the concentration of sVCAM-1 and correlated factors at different time: within 7 days, 3 months and 12 months later. Result ①The concentration of sVCAM-1 was higher than contrast after 7 days and 3 months with the treatment of atrovastatin.And the results are statistical meaning. ②The levels of TC and LDL were lower after 3 months and 12 months. ③The level of sVCAM-1 was lower after 3 months. ④There was no obvious difference 12 months later. Conclusion ①The level of sVCAM-1 rise in the secrum of acute cerebral thrombosis. ②Atrovastatin can reduce the levels of TC , LDL and sVCAM-1.